Breaking News, Collaborations & Alliances

Ascidian Therapeutics, Roche Enter Research Collaboration & License Agreement

Partner for the discovery and development of RNA exon editing therapeutics targeting neurological diseases.

Author Image

By: Charlie Sternberg

Associate Editor

Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, has entered a research collaboration and licensing agreement with Roche for the discovery and development of RNA exon editing therapeutics targeting neurological diseases.   Ascidian’s RNA exon editing platform is designed to advance the therapeutic possibilities of RNA medicine and treat diseases not addressed by today’s gene editing technologies. The company designs and develops RNA e...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters